NeoPharm Reports 1Q26 Operating Profit of KRW 87.0B, Up 11.9% YoY
-
2026 Q1 preliminary sales: KRW 362.2B (+14.6% YoY, -0.5% QoQ).
-
Operating profit: KRW 87.0B (+11.9% YoY, +20.6% QoQ).
-
Net income: KRW 86.2B (+20.9% YoY, +26.0% QoQ).
-
Results are preliminary on a separate basis (K-IFRS); comparative periods are consolidated due to subsidiary liquidation.
-
Unaudited internal data subject to change upon final settlement.
KOSDAQ Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: Neopharm (092730)
-
Submission: Neopharm Co., Ltd.
-
Receipt: 05-08-2026
-
Under KRX KOSDAQ Market Division